Opus Genetics Conference Participation Overview
Opus Genetics, Inc. (Nasdaq: IRD), a dynamic clinical-stage biopharmaceutical company, is dedicated to developing innovative gene therapies aimed at restoring vision and preventing blindness in individuals suffering from inherited retinal diseases. The Company has exciting participation lined up at some prominent investor conferences. These gatherings present a fantastic opportunity for stakeholders to gain insights into the groundbreaking work being done in the field of gene therapy for retinal disorders.
Upcoming Conferences Featuring Opus Genetics
The first event on the agenda is the BTIG 5th Annual Ophthalmology Day, where Dr. Ash Jayagopal, the Chief Scientific and Development Officer of Opus Genetics, will take part in a fireside chat. This engaging dialogue is scheduled for a virtual format, allowing attendees to learn from experts in the field regarding advancements in treatments relevant to ophthalmology. The chat will happen on a designated date, at 1:00 p.m. ET.
Following this, George Magrath, M.D., the Chief Executive Officer, is poised to participate in the Piper Sandler 37th Annual Healthcare Conference. This event will take place in New York, where he will share critical insights through another fireside chat on another specified date at 10:00 a.m. ET. This platform will help him convey company revelations to a broader investor audience.
Webcasting Opportunities
For those eager to access real-time insights, a link to both live and archived webcasts of the Piper Sandler conference will be available. Interested parties can find this valuable information through the Investors section on the Opus Genetics website, which serves as a hub for various company updates and events.
Understanding Opus Genetics and Its Mission
At its core, Opus Genetics operates with a clear mission: to develop effective gene therapies that can reverse the dire fates of patients afflicted with inherited retinal diseases (IRDs). The Company is committed to formulating durable and one-time treatments targeting the root genetic issues that lead to serious retinal conditions.
Notably, the Company’s innovative pipeline is populated with seven AAV-based programs. Among these programs, OPGx-LCA5 stands out for targeting mutations responsible for LCA5-related diseases, while OPGx-BEST1 aims to tackle BEST1-related retinal degeneration. In addition to these, Opus Genetics is developing therapies aimed at RHO, RDH12, and MERTK, providing hope for a variety of genetic challenges faced by patients.
Further Developments
In parallel with its gene therapy advancements, Opus Genetics is also pursuing the development of Phentolamine Ophthalmic Solution 0.75%. This approved small-molecule treatment is geared towards addressing pharmacologically induced mydriasis, with potential applications under evaluation for other conditions like presbyopia and low-light visual disturbances that might arise after keratorefractive surgeries.
Connecting with Opus Genetics
Opus Genetics prides itself on being at the forefront of biopharmaceutical development shown in its base in Research Triangle Park, NC. For anyone looking to delve deeper into the Company’s mission and innovative pipeline, the official website provides extensive resources, insights, and updates.
Stakeholders can remain connected through the investor communication channels, ensuring they stay abreast of developments that might impact the Company’s trajectory and success in the biopharmaceutical landscape.
Frequently Asked Questions
What does Opus Genetics specialize in?
Opus Genetics focuses on developing gene therapies specifically targeted at restoring vision and preventing blindness from inherited retinal diseases.
Which conferences will Opus Genetics attend?
Opus Genetics will participate in the BTIG 5th Annual Ophthalmology Day and the Piper Sandler 37th Annual Healthcare Conference.
Who are the key speakers representing Opus Genetics?
Dr. Ash Jayagopal, Chief Scientific and Development Officer, and Dr. George Magrath, Chief Executive Officer, will represent the Company at these events.
How can I watch the conferences?
The webcasting for the Piper Sandler conference can be accessed on the Opus Genetics website, specifically under the Investors section.
Where is Opus Genetics located?
Opus Genetics is based in Research Triangle Park, North Carolina, where it is advancing its innovative biopharmaceutical programs.
